Expanding the Effectiveness of Medical Procedures and Diagnosis
DH Medical is an early-stage medical software company using patented and tested methodologies and techniques to radically improve current limits of medical imaging, signal measurement and analysis.
Our products are designed to improve diagnostic accuracy, patient and provider safety and create new paradigms for therapies, treatment and care.
DH Medical launch product families have been chosen for maximum impact, easy integration into current systems and workflows, as well as providing the foundation for growth into other areas of life science innovation, new diagnostic and treatment patterns and other industries.
DH Medical launch product families have been chosen for maximum impact, easy integration into current systems and workflows, as well as providing the foundation for growth into other areas of life science innovation, new diagnostic and treatment patterns and other industries.
DH Medical PurePixel
A Revolutionary Breakthrough in Radiation Reduction in Fluoroscopy
“While radiation for CT, angio or fluoroscopy, no radiation is good radiation. My goal is to minimize radiation exposure for myself, my team, and my patients. Although we have no immediate indication of how much radiation we are exposed to – we all know the effects are cumulative, and when feeling effects like cancer, it’s too late. A neurointerventional radiology partner of mine died 2 years ago from a left-sided glioblastoma, undoubtably related to high radiation exposure over 30 years in practice. Technology that can reduce radiation while maintaining image quality is absolutely worth considering.”
Ryan Majoria, M.D. - Interventional and Diagnostic Radiologist, Radiology Associates, L.L.C., Baton Rouge, LA
For more than a century, radiographic image clarity has been structurally linked to radiation energy applied.
Radiation used in fluoroscopic procedures additionally use contrast agents to aid in soft tissue visualization, which can lead to nausea, discomfort, anaphylaxis, kidney damage, cardiac arrhythmias, respiratory or cardiac arrest and even seizures.
Effective radiation dosages in complex procedures can be 5-40 mSv which equates to an extra 2 to 35 years of effective radiation exposure. This increases long-term cancer risk for patients undergoing a procedure. This severely impacts providers and surgeons, causes health risks, and limits available patient surgical time.
Three Approaches to Reducting the Impact of Radiation
DH Medical PurePixel In Action
DH Medical PurePixel has been designed to significantly enhance images, add clarity and detail, shorten procedures, reduce radiation exposure for patients, providers and staff, and decrease toxic contrast agent requirements. DH Medical’s patented technology enhances input imagery using a brute force mathematical approach to modify pixel intensities purely from the input signal, which leads to far better diagnoses, better AI analysis, and better outcomes.
PurePixel enhances input imagery using a brute force mathematical approach to modify pixel intensities purely from the input signal. No machine-learned or data/model-trained aspects; pixel improvements use non-convolutional kernel-based operations based on statistical properties of input imagery/video. PurePixel preserves the original photogrammetry of inbound imagery, ensuring no modification, while enhancing clarity in fluoroscopic procedures or disgnostics.
An example of PurePixel from implementation in other industries:
DH Medical Precision Measuring Matrix (PMM)
DH Medical’s Product to Radically Improve Data Analysis to Change Cardiology and Prevent Congestive Heart Failure
Cardiac perturbations are not discreet events; they are part of a complex process with identifiable signals. However, many current techniques focus on identifying the peak event only, like heart failure. Our enhanced signal processing increases the quantity and quality of available data, potential for analysis, and diagnosis reliability and accuracy.
Mining previously undetected data in ECG streams provides enhanced input data for partners and our proprietary AI engine. We extract actionable signals from what is normally dismissed as noise. This provides clinicians with actionable data far earlier that will improve the treatment pathway for early disease detection.
Precision MeasuringMatrix (PMM) is patented signal processing technology that enables the capture of highly accurate time, frequency, and amplitude (TFA) information simultaneously, allowing for extraordinary multi-dimensional measurement, analysis and separation of complex waveforms and signals.
Remote Cardiac Monitors Produce Excessive False Positives
The trend in remote cardiac monitoring is hugely impactful, but limited by data analysis, false positives, and device battery life. DH Medical testing in 2024 indicates that the PMM can help eliminate nearly all false positives.
Systemic Chronic Heart Disease Requires Earlier Detection & Diagnosis
Conditions such as Congestive Heart Failure (CHF) are chronically un-detected with current techniques. The DH Medical PMM increases the amount of available data, ability to analyze it, and improve AI model outcomes by an order of magnitude.
About DH Medical
Background & Origins of Our Technology
Digital Harmonic was developed in 2016 by Paul Reed Smith, founder of PRS Guitars. Paul experimented with novel approaches to measuring waveforms which led to technologies that began to truly revolutionize the practice of signal and imaging processing with the launch of three core Digital Harmonic products:
Paul’s inventions became the origins of Digital Harmonic’s technology stack. Additional product solutions for extracting and analyzing signals across time, frequency and amplitude, as well as digital video, were launched with applications in defense, broadcasting, data processing, product development, and with the launch of DHM, healthcare diagnostics and surgical medicine applications.
Digital Harmonic holds 39 patents and has a suite of solutions in-market with government and private video broadcast customers, as well as dozens of additional R&D projects in the pipeline together with DH Medical.
Scott Haiges
Co-Founder, EVP Strategy
Scott has served as the CEO of Digital Harmonic since its inception, driving the company from initial concept through the commercialization of its products. Scott co-founded DH Medical after years of refining product-market fit. Prior to joining Digital Harmonic, Scott was EIR at the venture capital firm Aspire Ventures, joining after a successful exit of a medical marketing technology company that he founded.
DH Medical Team
Jim Alecxih
CEO
Jim brings a rich 35-year history in the medical device industry, including working with Intuitive Surgical from first revenue to over $2B in sales. Extensive product launch, early stage, and high growth experience and several successful go-to-market launches.
Dan Armstrong
COO
Dan is an experienced start-up and technology leader working in medtech, mobile telecommunications, satellite and financial services for 30+ years, with successful launches in over 40 countries.
He has worked in CGM insulin-delivery diabetes tech, design of innovative orthopedic surgery centers, early-stage fractal image format patents, and has a background in physics and audio engineering.
Paul Reed Smith
Co-Founder, Head of Innovation
Paul Reed Smith is a guitar maker, musician, founder, and Managing General Partner of Paul Reed Smith Guitars.
He is the founder of Digital Harmonic, DH Medical, CytoAcoustics and Biosonic Acoustics.
Mason Baron
CTO
With years of software development, AI, machine learning, surveillance reconnaissance systems design, imagery, signal, and radar processing experience, Mason leads DHM as CTO.
Mason served as Chief Engineer of Battle Force Projects at the Johns Hopkins University Applied Physics Laboratory prior to serving as Minotaur Chief Naval Architect at Alion Science & Technology.
DH Medical Scientific Advisory Board
William Nelson M.D., Ph.D.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Gene Frantz
Professor in the Practice, Electrical and Computer Engineering, Rice University
David Tuveson, M.D., Ph.D.
Cold Spring Harbor Laboratory, Roy J. Zuckerberg Professor of Cancer Research
Michael Hibler, MPA
Executive Director for Development, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Andrew von Eschenbach M.D.
Samaritan Health Initiatives, Inc., Fmr. FDA Commissioner, Fmr. Dir. National Cancer Institute
Srinivasan Yegnasubramanian, MD, PhD
Co-Dir. Computational Genomics Core, Johns Hopkins University School of Medicine
Dr. Andrew Weil
Andrew Weil Center for Integrative Medicine, University of Arizona
Joseph Amaral, MD
Vice President, Medical Affairs, Histosonics
Alexander S. Szalay, Ph.D.
Johns Hopkins Krieger School of Arts and Sciences, Physicist
John Moses, Ph.D.
Professor of Chemistry, Cold Spring Harbor Laboratory